Publication | Closed Access

Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial

Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineImmunologyPathologyPharmacotherapyCancer TreatmentPrimary Endpoint AnalysisOncologyCancer Research